Genentech - Exhibitor | |
---|---|
Contact Information: James Eggen Joy Bietz Jeff Carlson Google Meets Link |
For more than 40 years, we’ve been following the science, OCREVUS® (ocrelizumab) is a therapeutic monoclonal antibody that represents a different scientific approach to treating MS. It targets a type of immune cell called a CD20-positive B cell that plays a key role in the disease. OCREVUS is approved by the FDA to treat relapsing or primary progressive forms of multiple sclerosis (MS). OCREVUS is given once every six months by an intravenous (IV) infusion.1 FIRST AND ONLY approved disease-modifying therapy for primary progressive multiple sclerosis (PPMS), a highly disabling form of MS1,2 |